This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Recommended Stories
- Five stocks we like better than Moleculin Biotech
- What is the Nikkei 225 index?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Investing in Commodities: What Are They? How to Invest in Them
- Applied Materials Market Capitulates: Now is the Time to Buy
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Ultra-High Dividend Yield Stocks for the New Year
